Diltiazem hydrochloride represents one of the most significant calcium channel blockers in modern cardiovascular pharmacology. This comprehensive article explores its chemical properties, clinical applications, and safety profile, providing healthcare professionals with essential information about this widely prescribed medication.
Introduction
Diltiazem hydrochloride is a benzothiazepine-derived calcium channel blocker that has been a cornerstone in cardiovascular pharmacotherapy since its approval by the U.S. Food and Drug Administration in 1982. Marketed under various brand names, with Cardizem being the most recognized, diltiazem has established itself as a versatile agent for managing several cardiovascular conditions.
It belongs to the nondihydropyridine class of calcium channel blockers, distinguished by its ability to affect both vascular smooth muscle and cardiac conduction tissue. In 2022, diltiazem ranked as the 100th most commonly prescribed medication in the United States, with over 6 million prescriptions filled, highlighting its continued clinical importance. The drug’s efficacy in treating hypertension, angina pectoris, and certain cardiac arrhythmias has maintained its relevance in therapeutic regimens despite the introduction of newer antihypertensive agents.
Chemical Structure
Diltiazem hydrochloride is chemically described as [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate hydrochloride. Its molecular formula is C₂₂H₂₆N₂O₄S·HCl with a molecular weight of 450.99 g/mol. Structurally, diltiazem features a 1,4-thiazepine ring system, which classifies it as a benzothiazepine-type calcium channel blocker, distinguishing it from other calcium channel blockers like dihydropyridines (e.g., amlodipine) and phenylalkylamines (e.g., verapamil).
The molecule contains two stereocenters, both with S configuration, and the therapeutic activity is attributed to the (2S,3S)-isomer. This specific stereochemistry is essential for its calcium channel blocking activity and subsequent pharmacological effects. The hydrochloride salt form improves the compound’s solubility in water, enhancing its pharmaceutical formulation and bioavailability.
Diltiazem-Based Medicines List
Below are the top eight diltiazem-based medications currently available on the market:
- Cardizem – The original brand name formulation of diltiazem, available in immediate-release tablets
- Cardizem CD – A controlled-delivery formulation allowing for once-daily dosing
- Cardizem LA – A long-acting formulation specifically designed for extended release over 24 hour
- Cartia XT – An extended-release formulation with a unique delivery system
- Dilt-XR – Another extended-release generic formulation of diltiazem
- Dilacor-XR – An extended-release formulation focusing on consistent blood levels
- Tiazac – A unique extended-release preparation of diltiazem hydrochloride
- Dilticard – A formulation available in some international markets
These medications differ primarily in their release mechanisms, which affect dosing frequency and potentially influence side effect profiles.
Mechanism of Action
Diltiazem exerts its therapeutic effects through a well-characterized mechanism involving calcium channel blockade. It specifically targets L-type calcium channels, binding to the alpha-1 subunit in a fashion similar to verapamil. The binding site is thought to be located at the S5-6 linker region of transmembrane domain IV and/or S6 segment of domain III. By blocking these channels, diltiazem inhibits the influx of extracellular calcium ions into cardiac and vascular smooth muscle cells during depolarization.
This calcium channel blockade produces several physiological effects. In vascular smooth muscle, reduced intracellular calcium concentrations promote relaxation, resulting in arterial vasodilation and decreased peripheral vascular resistance. This vasodilation is more potent in coronary arteries than in peripheral vessels, which accounts for its efficacy in treating angina.
In cardiac tissue, diltiazem exhibits negative inotropic (decreased contractility), chronotropic (decreased heart rate), and dromotropic (slowed conduction) effects. These combined actions decrease myocardial oxygen demand while simultaneously increasing oxygen supply through coronary vasodilation.
Unlike dihydropyridine calcium channel blockers, diltiazem has significant effects on cardiac conduction, particularly at the atrioventricular node, which explains its utility in managing certain supraventricular arrhythmias. This multifaceted mechanism allows diltiazem to address various cardiovascular conditions with a single therapeutic agent.
Pharmacokinetics
The pharmacokinetic profile of diltiazem hydrochloride provides important insights into its clinical application. Following oral administration, diltiazem is rapidly and well absorbed from the gastrointestinal tract but undergoes extensive first-pass metabolism in the liver, resulting in an absolute bioavailability of approximately 40%. However, there is significant interindividual variation, with bioavailability ranging from 24% to 74%. After a single oral dose, immediate-release formulations produce peak plasma concentrations within 30-60 minutes.
Diltiazem is 70-80% bound to plasma proteins, with approximately 40% bound to alpha-1-glycoprotein and 30% to albumin. The drug demonstrates an apparent volume of distribution of approximately 305 L following intravenous administration, indicating extensive tissue distribution.
Metabolically, diltiazem undergoes extensive hepatic biotransformation via the cytochrome P450 system, primarily through CYP3A4-mediated N-demethylation, O-demethylation, and deacetylation. The principal active metabolite, deacetyldiltiazem, retains 25-50% of the pharmacological activity of the parent compound. Other metabolites include N-monodesmethyl diltiazem and deacetyl N-monodesmethyl diltiazem.
The plasma elimination half-life of diltiazem ranges from 3.0 to 4.5 hours after oral administration. Extended-release formulations have apparent elimination half-lives of 6-9 hours. The drug is primarily eliminated through the hepatobiliary route, with only 2-4% of unchanged diltiazem appearing in the urine.
Therapeutic Uses
Diltiazem hydrochloride has been approved for multiple cardiovascular indications, demonstrating its versatility in clinical practice:
| Condition | Mechanism of Benefit | Dosage Forms | Notes |
|---|---|---|---|
| Hypertension | Peripheral arterial vasodilation reducing systemic vascular resistance | Oral (immediate and extended-release) | Particularly effective in low-renin hypertension |
| Stable Angina | Coronary vasodilation and reduced myocardial oxygen demand | Oral (immediate and extended-release) | Increases exercise tolerance |
| Variant (Prinzmetal’s) Angina | Direct coronary artery dilation | Oral | Particularly effective if mechanism is vasospasm |
| Unstable Angina | Coronary dilation and decreased myocardial oxygen demand | Oral | Used cautiously due to negative inotropic effects |
| Atrial Fibrillation/Flutter | Slowed AV nodal conduction controlling ventricular rate | Oral and IV | Initial IV bolus of 0.25 mg/kg |
| Supraventricular Tachycardia | AV nodal blockade | IV | As effective as verapamil in PSVT |
| Myocardial Bridge | Reduced cardiac contractility | Oral | Off-label use |
| Anal Fissures | Local vasodilation promoting healing | Topical | Off-label use |
Side Effects
Diltiazem hydrochloride, while generally well-tolerated, can produce a range of adverse effects related to its pharmacological actions. Common side effects include peripheral edema (occurring in up to 15% of patients), headache, dizziness, and flushing. These vasodilatory effects tend to be dose-related and may be more pronounced in elderly patients.
Cardiovascular side effects deserve special attention given the drug’s primary indications. These include bradycardia, various degrees of atrioventricular (AV) block, hypotension, and palpitations. In rare cases, diltiazem can exacerbate or precipitate heart failure due to its negative inotropic effects, particularly in patients with pre-existing ventricular dysfunction.
Gastrointestinal disturbances such as nausea, constipation, and dyspepsia are relatively common but rarely necessitate discontinuation. Diltiazem can also cause mild elevations in liver function tests, and although rare, cases of hepatic injury have been reported, particularly early in therapy (1-8 weeks after initiation).
Other reported adverse effects include flu-like symptoms, respiratory infections, fatigue, and dermatological reactions. Severe hypersensitivity reactions, though uncommon, may manifest as skin rashes, including rare cases of Stevens-Johnson syndrome. Particular vigilance is warranted during the initial weeks of therapy for any signs of idiosyncratic reactions or pronounced hemodynamic effects.
Drug Interactions
Diltiazem hydrochloride’s inhibitory effect on CYP3A4 makes it prone to numerous clinically significant drug interactions. Understanding these interactions is vital for safe prescribing practices.
Diltiazem has severe interactions with dantrolene (risk of hyperkalemia and cardiovascular collapse), flibanserin (increased risk of hypotension and syncope), lomitapide (increased plasma concentrations due to CYP3A4 inhibition), lonafarnib, and pimozide (risk of QT prolongation). Additionally, it has documented serious interactions with at least 75 other medications and moderate interactions with more than 260 drugs.
Particular attention should be paid to interactions with other cardiovascular medications. Concurrent use with beta-blockers may enhance bradycardia and AV block or precipitate heart failure in susceptible patients. Diltiazem can increase serum concentrations of digoxin, leading to potential toxicity. When combined with other antihypertensives, enhanced hypotensive effects may occur, requiring dose adjustments.
Other notable interactions include increased plasma concentrations of statins (especially simvastatin), cyclosporine, tacrolimus, and certain benzodiazepines metabolized by CYP3A4. Comprehensive medication reconciliation is essential when initiating or adjusting diltiazem therapy, especially in patients on complex medication regimens.
Safety Considerations
Several safety considerations guide appropriate use of diltiazem hydrochloride. The drug is relatively contraindicated in several clinical scenarios, including sick sinus syndrome, advanced atrioventricular conduction disturbances unless a functional pacemaker is present, severe hypotension (systolic blood pressure <90 mm Hg), and acute myocardial infarction with pulmonary congestion. Caution is warranted in patients with impaired left ventricular function due to diltiazem’s negative inotropic effects, which could precipitate or worsen heart failure.
In patients with Wolff-Parkinson-White syndrome, diltiazem may paradoxically increase ventricular rate due to accessory conduction pathways. This represents an important consideration when treating arrhythmias.
Regarding hepatic and renal impairment, diltiazem should be used with caution in patients with hepatic dysfunction as systemic clearance is reduced and half-life is prolonged in cirrhosis. Although specific dosage recommendations for renal impairment are not available, evidence suggests that the pharmacokinetics of diltiazem may not be substantially altered in patients with renal failure.
Pregnancy considerations are also important; diltiazem is not recommended during pregnancy due to limited data on safety. Additionally, caution should be exercised when discontinuing therapy, as abrupt withdrawal may exacerbate angina symptoms, necessitating gradual dose reduction.
Regulatory Status
Diltiazem hydrochloride received FDA approval for medical use in the United States in 1982, marking over four decades of clinical use. It is available as both brand-name products and generic formulations, which has increased its accessibility to patients. Various formulations have been developed and approved over the years, including immediate-release tablets, extended-release capsules, and intravenous preparations for acute management of certain arrhythmias.
As of 2022, diltiazem was the 100th most commonly prescribed medication in the United States, with more than 6 million prescriptions filled annually, demonstrating its continued clinical relevance despite the introduction of newer cardiovascular agents. It is classified as a prescription-only medication in most jurisdictions worldwide and is included in various national formularies and essential medicine lists for the management of cardiovascular conditions.
Regulatory bodies continually evaluate the safety profile of diltiazem, with periodic safety updates required from manufacturers. Post-marketing surveillance has helped refine understanding of rare adverse effects and interactions, contributing to the comprehensive safety information available to prescribers today.
Conclusion
Diltiazem hydrochloride remains an important agent in the management of various cardiovascular conditions, offering a unique pharmacological profile that distinguishes it from other classes of antihypertensive and anti-anginal medications. Its efficacy in hypertension, angina, and certain arrhythmias, combined with its generally favorable tolerability, ensures its continued place in therapeutic algorithms.
However, clinicians must remain vigilant regarding its potential interactions and contraindications, particularly in patients with pre-existing cardiac conduction abnormalities or heart failure. With proper patient selection and monitoring, diltiazem hydrochloride continues to serve as a valuable tool in the management of cardiovascular disease.
